Cellceutix Corporation (CTIX)

Ein Kommentar / 0 new
Bild des Benutzers Hans
Zuletzt online: 11.08.2016
Mitglied seit: 22.05.2006
Kommentare: 1'967
Cellceutix Corporation (CTIX)

http://cellceutix.com/ Company Address:100 Cumming Center, Suite 151-BBeverly, MA 01915Phone: 978-236-8717Fax:  978-921-6564Email:  info@cellceutix.com Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Management:   http://cellceutix.com/team/ Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Se... Product Pipeline:  http://cellceutix.com/Pipeline/ Recent News and Press Releases: http://finance.yahoo.com/q/h?s=CTIX+Headlines Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX http://cellceutix.com/category/press-release/ SEC Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&C... Cellceutix IP - Patent Filings:EPOhttp://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&loc...WIPOhttp://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&...(Cellceutix)&maxRec=1USPTOhttp://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=... Publication number US8338454 B2Publication type GrantApplication number US 12/780,132Publication date Dec 25, 2012Filing date May 14, 2010Priority date May 20, 2009Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454 B2 http://www.google.com/patents/US8338454 http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=... Investor Relations:  info@cellceutix.com Aktueller Kurs: $ 2,09